EyePoint's Phase 3 failure; Lilly's China drug delivery deal
Plus news about Longwood's next fund and Ryzumvi's label expansion. EyePoint drug fails, biotech halves staff: The Watertown, MA-based biotech is letting go of 53% of its positions after its experimental ...
SHANGHAI, Oct. 19, 2026 - Mabwell, a biopharmaceutical company based in Shanghai, will showcase Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 during the 2026 European Society for Medical Oncology (ESMO) Congress. The study examines the potential of 9MW2821 in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously received an ADC containing topoisomerase I inhibitor payload.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
